However, it is important to note that while FLI-1 is a sensitive marker for AS, its expression has also been detected in benign vascular tumors, such as hemangiomas (129), or other non-endothelial neoplasms, such as Ewing’s sarcoma, erythroleukemia, lymphoma (164–166). Here, FLI1 is linked to erythroleukemia.